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Letters to the EditorReply to: ‘‘Might some of the beneﬁcial effects of the Mediterranean
diet on non-alcoholic fatty liver disease be mediated
by reduced iron stores?’’Reduction of iron stores: An additional potential beneﬁt of the
Mediterranean diet in non-alcoholic fatty liver disease?
also noted that in a recent paper by Kowdley et al. [8], the neg-
ative effects of iron in an animal model were ameliorated by
oleic acid, which was abundant in the diet studied in our paper,
providing an additional potential mechanism by which our diet
could have reduced insulin sensitivity and steatosis. Overall, we
agree that Mascitelli and colleagues provide evidence for an
intriguing alternative beneﬁt of the Mediterranean diet in
NAFLD.
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We thank Mascitelli et al. for their comments regarding our study
on the effects of the Mediterranean diet on hepatic steatosis and
insulin sensitivity [1]. Mascitelli suggests that because of the rel-
atively low red meat content of the Mediterranean diet (MD),
there is a relatively reduced intake of iron, which may be a poten-
tial mechanism improving insulin sensitivity and steatosis. We
believe that although there is merit in the comments, we would
like to dispute some of the statements made.
Firstly, Mascitelli and colleagues state that serum ferritin is a
good marker of iron stores in NAFLD. We suggest that whilst in
healthy non-diabetic subjects, serum ferritin is strongly associ-
ated with hepatic iron stores, in NAFLD this is not the case. In
fact, dysmetabolic subjects often have high serum ferritin levels,
being the so-called dysmetabolic hyperferritinaemia (DHF) the
commonest cause of mild to moderate hyperferritinaemia in
clinical practice [2]. As non-alcoholic fatty liver disease (NAFLD)
is associated with systemic inﬂammation, increased adipokine
release and oxidative and endoplasmic reticulum stress, the
assessment of iron status is particularly challenging in these
patients.
However, we agree that hyperferritinaemia has been associ-
ated with hepatic histological damage in NAFLD [3]. A recent
paper published by the Non-alcoholic Steatohepatitis Clinical
Research Network (NASH CRN) demonstrated that in subjects
with NASH, a serum ferritin >1.5  ULN was associated with
increased iron deposition, but was also independently associated
with a higher NAFLD activity score (NAS) and was a predictor of
advanced ﬁbrosis regardless of iron deposition [4].
Hyperferritinaemia is also known to be associated with
reduced insulin sensitivity. It is a predictor of development of
type 2 diabetes, as well as more rapid progression of cardiovas-
cular disease [5]. In another study, both serum ferritin and
hepcidin levels increased linearly with the number of metabolic
syndrome features [6]. Therefore, it is likely that the hyperferri-
tinaemia seen in NASH is reﬂective of reduced insulin sensitivity
and the presence of the metabolic syndrome rather than of
iron overload. However, it is still unclear which is the nature
of the relationship between iron and insulin sensitivity: is
ferritin reﬂective of pathological iron levels that affect IGF-1/
insulin signaling [7], or is it simply a marker of the subsequent
inﬂammation and cytokine release that accompanies insulin
resistance?
Our subjects underwent baseline ferritin estimations but not
follow-up assays, so we can only provide cross-sectional data.
Overall, there was no signiﬁcant association between serum iron
and hepatic ﬁbrosis or NAS score, however, this may be because
of the small numbers involved.
In our dietary intervention, subjects were exposed to four-
week diets. We doubt that this would provide sufﬁcient time
for the iron stores to be altered to a sufﬁcient degree as to make
any difference to insulin sensitivity or steatosis. However, we640 Journal of Hepatology 2013 vol. 59 j 631–640
